ESCV Membership
(Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 5, 2018 Category: Virology Source Type: research
PASCV Membership
(Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 5, 2018 Category: Virology Source Type: research
Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: Detection by the Elecsys ® HBsAg II assay
Nearly 250 million people worldwide have chronic hepatitis B virus (HBV) infection, which can lead to long-term complications, such as cirrhosis, liver failure and hepatocellular carcinoma [1,2]. HBV is differentiated into a number of genotypes, which are characterized by differences of>8% in genome sequence; 10 HBV genotypes (A –J) have been identified to date, with distinct geographic distributions [3]. For example, genotype C is primarily found in South-East Asia, and genotype I has been reported in Vietnam and Laos [3]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 5, 2018 Category: Virology Authors: Hyon Suk Kim, Xinyue Chen, Min Xu, Cunling Yan, Yali Liu, Haohui Deng, Bui Huu Hoang, Pham Thi Thu Thuy, Terry Wang, Yiwen Yan, Zhen Zeng, Mikael Gencay, Gaston Westergaard, Stephan Pabinger, Albert Kriegner, Markus Nauck, Anja Seffner, Peter Gohl, Kirste Source Type: research
Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: detection by the Elecsys ® HBsAg II assay
Nearly 250 million people worldwide have chronic hepatitis B virus (HBV) infection, which can lead to long-term complications, such as cirrhosis, liver failure and hepatocellular carcinoma [1,2]. HBV is differentiated into a number of genotypes, which are characterized by differences of>8% in genome sequence; 10 HBV genotypes (A –J) have been identified to date, with distinct geographic distributions [3]. For example, genotype C is primarily found in South-East Asia, and genotype I has been reported in Vietnam and Laos [3]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 5, 2018 Category: Virology Authors: Hyon Suk Kim, Xinyue Chen, Min Xu, Cunling Yan, Yali Liu, Haohui Deng, Bui Huu Hoang, Pham Thi Thu Thuy, Terry Wang, Yiwen Yan, Zhen Zeng, Mikael Gencay, Gaston Westergaard, Stephan Pabinger, Albert Kriegner, Markus Nauck, Anja Seffner, Peter Gohl, Kirste Source Type: research
Evaluation of the Architect HIV Ag/Ab Combo Assay in a low-prevalence setting: The role of samples with a low S/CO ratio
The complexity of the HIV-1 epidemic has been increasing worldwide, reaching a highly heterogeneous distribution of HIV-1 subtypes/sub-subtypes that varies geographically [1 –3]. On the other hand, the diagnosis of HIV infection has evolved considerably since the development of the first serological screening tests in 1985. Nowadays, the most widely used are fourth-generation ELISAs, which can detect both antigens (p24) and antibodies against HIV-1 and HIV-2. These as says have been extensively evaluated and have proven to have high sensitivity and specificity, thus narrowing the window period and enabling the detection ...
Source: Journal of Clinical Virology - April 4, 2018 Category: Virology Authors: Roberto Alonso, Felipe P érez-García, Paloma Gijón, Ana Collazos, Emilio Bouza Source Type: research
Molecular features of Hepatitis E Virus circulation in environmental and human samples
Hepatitis E virus (HEV) is suspected to be a food- and water- transmitted virus with a zoonotic cycle especially for HEV genotype 3 (HEV3) [1]. HEV1 and HEV2 are restricted to humans and transmitted through contaminated water in developing countries. HEV3 and HEV4 genotypes can infect humans, pigs and other mammals [2,3]. HEV5 and HEV6 were detected in wild boars in Japan and HEV7 in camels [4,5]. However, HEV circulation between human beings, animals and the environment remains misunderstood and has been investigated for the present study in North Eastern France where quite a high HEV prevalence in humans was observed [6]...
Source: Journal of Clinical Virology - April 4, 2018 Category: Virology Authors: H. Fenaux, M. Chassaing, S. Berger, H. Jeulin, A. Gentilhomme, M. Bensenane, J.P. Bronowicki, C. Gantzer, I. Bertrand, E. Schvoerer Source Type: research
Evaluation of the Architect HIV Ag/Ab Combo Assay in a low-prevalence setting: the role of samples with a low S/CO ratio
The complexity of the HIV-1 epidemic has been increasing worldwide, reaching a highly heterogeneous distribution of HIV-1 subtypes/sub-subtypes that varies geographically [1 –3]. On the other hand, the diagnosis of HIV infection has evolved considerably since the development of the first serological screening tests in 1985. The most widely used today are fourth-generation ELISAs, which can detect both antigens (p24) and antibodies against HIV-1 and HIV-2. These assays have been extensively evaluated and have proven to have high sensitivity and specificity, thus narrowing the window period and enabling the detection of ac...
Source: Journal of Clinical Virology - April 4, 2018 Category: Virology Authors: Roberto Alonso, Felipe P érez-García, Paloma Gijón, Ana Collazos, Emilio Bouza Source Type: research
Molecular features of Hepatitis E Virus circulation in environmental and human samples
Hepatitis E virus (HEV) is suspected to be a food- and water- transmitted virus with a zoonotic cycle especially for HEV genotype 3 (HEV3) [1]. HEV1 and HEV2 are restricted to humans and transmitted through contaminated water in developing countries. HEV3 and HEV4 genotypes can infect humans, pigs and other mammals [2,3]. HEV5 and HEV6 were detected in wild boars in Japan and HEV7 in camels [4,5]. However, HEV circulation between human beings, animals and the environment remains misunderstood and has been investigated for the present study in North Eastern France where quite a high HEV prevalence in humans was observed [6]...
Source: Journal of Clinical Virology - April 4, 2018 Category: Virology Authors: H. Fenaux, M. Chassaing, S. Berger, H. Jeulin, A. Gentilhomme, M. Bensenane, J.P. Bronowicki, C. Gantzer, I. Bertrand, E. Schvoerer Source Type: research
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment
Genotypic resistance test (GRT) performed in peripheral blood mononuclear cells (PBMC) represents a chance to evaluate resistance in virologically suppressed HIV infected patients. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 3, 2018 Category: Virology Authors: Daniele Armenia, Mauro Zaccarelli, Vanni Borghi, William Gennari, Domenico Di Carlo, Alberto Giannetti, Federica Forbici, Ada Bertoli, Caterina Gori, Lavinia Fabeni, Carmela Pinnetti, Raffaella Marocco, Alessandra Latini, Francesca Ceccherini-Silberstein, Tags: Short communication Source Type: research
Rare emergence of drug resistance in HIV-1 treatment-na ïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
Combination antiretroviral therapy containing 3 HIV-1 antiviral drugs has been the cornerstone for the treatment of HIV-1 infection for over 2 decades, while the advent of once-daily single tablet regimens have simplified treatment and greatly improved the quality of life of people burdened by HIV-1 infection [1]. The single-tablet regimen studied here, comprising the 3 antiviral drugs elvitegravir (EVG or E), emtricitabine (FTC or F), and tenofovir alafenamide (TAF) as well as the pharmaco-enhancer cobicistat (C) (known as Genvoya ® or E/C/F/TAF), is one of the latest complete HIV-1 treatment to gain regulatory approval ...
Source: Journal of Clinical Virology - April 2, 2018 Category: Virology Authors: Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D. Miller, Christian Callebaut Source Type: research
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART
The influence of HIV-1 co-receptor usage on the course of therapy in subjects fully responding to ART has been poorly investigated. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 2, 2018 Category: Virology Authors: Francesca Lombardi, Simone Belmonti, Lucrezia Rapone, Alberto Borghetti, Arturo Ciccullo, Roberta Gagliardini, Gianmaria Baldin, Francesca Montagnani, Davide Moschese, Arianna Emiliozzi, Barbara Rossetti, Andrea De Luca, Simona Di Giambenedetto Source Type: research
Rare Emergence of Drug Resistance in HIV-1 Treatment-Na ïve Patients Receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for 144 Weeks
Combination antiretroviral therapy containing 3 HIV-1 antiviral drugs has been the cornerstone for the treatment of HIV-1 infection for over 2 decades, while the advent of once-daily single tablet regimens have simplified treatment and greatly improved the quality of life of people burdened by HIV-1 infection [1]. The single-tablet regimen studied here, comprising the 3 antiviral drugs elvitegravir (EVG or E), emtricitabine (FTC or F), and tenofovir alafenamide (TAF) as well as the pharmaco-enhancer cobicistat (C) (known as Genvoya ® or E/C/F/TAF), is one of the latest complete HIV-1 treatment to gain regulatory approval ...
Source: Journal of Clinical Virology - April 2, 2018 Category: Virology Authors: Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D. Miller, Christian Callebaut Source Type: research
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART
The entry of human immunodeficiency virus type 1 (HIV-1) into target cells requires the use of at least one of two distinct surface chemokine co-receptors, CCR5 (R5) or CXCR4 (X4). Viruses may use R5 (R5-tropic viruses) or X4 (X4-tropic) individually or use both R5 and X4 (dual or mixed-tropic virus) [1 –3]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - April 2, 2018 Category: Virology Authors: Francesca Lombardi, Simone Belmonti, Lucrezia Rapone, Alberto Borghetti, Arturo Ciccullo, Roberta Gagliardini, Gianmaria Baldin, Francesca Montagnani, Davide Moschese, Arianna Emiliozzi, Barbara Rossetti, Andrea De Luca, Simona Di Giambenedetto Source Type: research
Trends in testing algorithms used to diagnose HIV infection, 2011 –2015, United States and 6 dependent areas
The Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention Strategic Plan 2017 –2020 has four main goals for prevention of human immunodeficiency virus (HIV) infection: 1) prevent new HIV infections, 2) improve health outcomes for persons living with HIV, 3) reduce HIV-related disparities and health inequities, and 4) continually improve effectiveness and efficiency of opera tions [1]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 26, 2018 Category: Virology Authors: Anne Harwood Peruski, Xueyuan Dong, Richard M. Selik Source Type: research
